AP1917A - Azaindoles - Google Patents

Azaindoles

Info

Publication number
AP1917A
AP1917A AP2006003492A AP2006003492A AP1917A AP 1917 A AP1917 A AP 1917A AP 2006003492 A AP2006003492 A AP 2006003492A AP 2006003492 A AP2006003492 A AP 2006003492A AP 1917 A AP1917 A AP 1917A
Authority
AP
ARIPO
Prior art keywords
azaindoles
Prior art date
Application number
AP2006003492A
Other languages
English (en)
Other versions
AP2006003492A0 (en
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Chris Edlin
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of AP2006003492A0 publication Critical patent/AP2006003492A0/xx
Application granted granted Critical
Publication of AP1917A publication Critical patent/AP1917A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
AP2006003492A 1999-12-24 2000-12-27 Azaindoles AP1917A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (en) 1999-12-24 2000-12-27 Azaindoles

Publications (2)

Publication Number Publication Date
AP2006003492A0 AP2006003492A0 (en) 2006-02-28
AP1917A true AP1917A (en) 2008-11-12

Family

ID=26316153

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.
AP2006003492A AP1917A (en) 1999-12-24 2000-12-27 Azaindoles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.

Country Status (27)

Country Link
US (2) US6770643B2 (cs)
EP (2) EP1263759B1 (cs)
JP (1) JP5436507B2 (cs)
KR (2) KR100755622B1 (cs)
CN (2) CN100379734C (cs)
AP (2) AP1587A (cs)
AU (1) AU777717B2 (cs)
BG (2) BG66066B1 (cs)
BR (1) BR0017038A (cs)
CA (2) CA2699568C (cs)
CY (1) CY1110951T1 (cs)
CZ (2) CZ301750B6 (cs)
DZ (1) DZ3377A1 (cs)
EA (1) EA005212B1 (cs)
EE (1) EE05180B1 (cs)
HK (1) HK1050191B (cs)
HR (1) HRP20020547B1 (cs)
HU (1) HUP0203895A3 (cs)
IL (3) IL150388A0 (cs)
MA (1) MA26857A1 (cs)
MX (1) MXPA02006338A (cs)
NO (2) NO323766B1 (cs)
NZ (1) NZ519121A (cs)
OA (1) OA12514A (cs)
PL (1) PL209572B1 (cs)
SK (2) SK288019B6 (cs)
WO (1) WO2001047922A2 (cs)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2679459B2 (ja) 1991-08-02 1997-11-19 王子製紙株式会社 感熱記録体
AU777717B2 (en) 1999-12-24 2004-10-28 Aventis Pharma Limited Azaindoles
PT1363705E (pt) * 2001-02-02 2012-08-17 Bristol Myers Squibb Co Composição e actividade antiviral de derivados de piperazina azaindoleoxoacética substituídos
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
EP1490365B1 (en) * 2002-03-28 2010-02-10 Eisai R&D Management Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
WO2003087087A2 (en) * 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
MXPA05001688A (es) 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
KR101415503B1 (ko) 2003-07-17 2014-07-04 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2589779A1 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
JP2008521768A (ja) * 2004-12-23 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
JP5015154B2 (ja) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US20070149506A1 (en) * 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PL2343299T3 (pl) * 2005-12-13 2016-09-30 Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
KR20080083680A (ko) * 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
CA2651732C (en) * 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
WO2008014249A2 (en) * 2006-07-24 2008-01-31 Sanofi-Aventis Improved preparations of 2 -substituted pyrrolo [2, 3-b] pyrazine ( 4, 7 -diazaindole ) compounds
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
JP5480813B2 (ja) * 2007-11-16 2014-04-23 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
JP5284377B2 (ja) 2008-02-25 2013-09-11 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
JP5368485B2 (ja) * 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
CA2716223A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
WO2009106441A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
NZ587906A (en) * 2008-03-10 2011-12-22 Sanofi Aventis Treatment for ocular-related disorders
RS55263B1 (sr) 2008-03-11 2017-02-28 Incyte Holdings Corp Derivati azetidina i ciklobutana kao jak inhibitori
CA2722326A1 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (en) * 2008-10-21 2010-04-29 Syngenta Participations Ag Diaza-indole derivatives and their use as fungicides
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
ME03556B (me) * 2009-05-22 2020-07-20 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1 h-pirazol-1-il]oktan- ili нертan - niтril kао јак inhibiтori
NZ596479A (en) * 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102471345A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
CA2771939A1 (en) 2009-08-26 2011-03-03 Nycomed Gmbh Methylpyrrolopyridinecarboxamides
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
EA023444B1 (ru) * 2010-02-18 2016-06-30 Инсайт Холдингс Корпорейшн Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
WO2011109932A1 (en) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Novel process for the manufacture of 5-halogenated-7-azaindoles
RS54823B1 (sr) 2010-03-10 2016-10-31 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
RU2012152354A (ru) * 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг Производные пирролопиразина в качестве ингибиторов syk и jak
MX338228B (es) 2010-05-21 2016-04-08 Incyte Corp Formulacion topica para inhibidor de cinasas janus (jak).
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
NZ611151A (en) 2010-11-19 2015-06-26 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EA026317B1 (ru) 2011-02-18 2017-03-31 Новартис Фарма Аг КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
AU2012253885A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
WO2012154520A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
PH12013502612A1 (en) 2011-06-20 2014-04-28 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
CA2863717C (en) * 2012-02-21 2021-09-28 Lars Burgdorf Furopyridine derivatives
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
BR112015001545B1 (pt) 2012-07-26 2022-07-05 Glaxo Group Limited Composto, composição farmacêutica, e, uso de um composto
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
TW201922255A (zh) 2012-11-15 2019-06-16 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
EP2970278A4 (en) * 2013-03-14 2016-12-07 Abbvie Inc Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
UY35419A (es) * 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PL2970265T3 (pl) 2013-03-15 2018-11-30 Plexxikon Inc. Heterocykliczne związki i ich zastosowania
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN112375067B (zh) * 2014-12-11 2024-03-15 贝达医药公司 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018191587A1 (en) * 2017-04-14 2018-10-18 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
EP3638241B1 (en) 2017-06-16 2022-05-25 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
KR20210018203A (ko) 2018-03-30 2021-02-17 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US11738026B2 (en) 2019-11-22 2023-08-29 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102818206B1 (ko) * 2021-07-12 2025-06-11 한양대학교 에리카산학협력단 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (en) * 1996-11-19 1998-05-28 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO1998047889A1 (en) * 1997-04-23 1998-10-29 Novartis Ag Chroman derivatives
WO1999020624A1 (en) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Bicyclic kinase inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) * 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
WO1995033748A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ATE231148T1 (de) 1996-07-13 2003-02-15 Glaxo Group Ltd Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
AU4054197A (en) 1996-08-14 1998-03-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
AU7132998A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
CA2293621C (en) * 1997-08-05 2003-12-30 Robert Lee Dow 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
CA2326143A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326184A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051234A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002510628A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
CA2326185A1 (en) * 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CN1308622A (zh) 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的联苯基氧代－乙酸
DE69942801D1 (de) 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
CA2344262A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
DK1144367T3 (da) 1998-12-31 2005-01-31 Aventis Pharma Inc Alfa-Substitution af ubeskyttede beta-aminoestere
AU5314900A (en) 1999-06-04 2000-12-28 Elan Pharma International Limited Compositions and methods for inhibiting cell death
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
AU777717B2 (en) 1999-12-24 2004-10-28 Aventis Pharma Limited Azaindoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
WO2001082930A1 (en) * 2000-05-03 2001-11-08 Tularik Inc. Pyrazole antimicrobial agents
WO2001096336A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2422379C (en) 2000-09-15 2008-11-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (en) * 1996-11-19 1998-05-28 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO1998047889A1 (en) * 1997-04-23 1998-10-29 Novartis Ag Chroman derivatives
WO1999020624A1 (en) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Bicyclic kinase inhibitors

Also Published As

Publication number Publication date
BG66176B1 (bg) 2011-11-30
MXPA02006338A (es) 2002-12-13
CN1413213A (zh) 2003-04-23
PL209572B1 (pl) 2011-09-30
HUP0203895A3 (en) 2004-09-28
CN100379734C (zh) 2008-04-09
KR20020062663A (ko) 2002-07-26
BG110623A (bg) 2010-07-30
SK9012002A3 (en) 2003-04-01
CA2699568A1 (en) 2001-07-05
EP1990343B1 (en) 2012-04-04
EP1263759B1 (en) 2010-09-08
SK287882B6 (sk) 2012-02-03
NO20023032D0 (no) 2002-06-21
NO323766B1 (no) 2007-07-02
NZ519121A (en) 2004-05-28
IL150388A (en) 2010-11-30
EP1990343A2 (en) 2008-11-12
BG106836A (bg) 2003-04-30
EA005212B1 (ru) 2004-12-30
EE05180B1 (et) 2009-06-15
US20040198737A1 (en) 2004-10-07
US20040009983A1 (en) 2004-01-15
AP2002002516A0 (en) 2002-06-30
EP1263759A2 (en) 2002-12-11
OA12514A (en) 2006-05-29
PL355819A1 (en) 2004-05-17
HRP20020547A2 (hr) 2005-10-31
CZ301751B6 (cs) 2010-06-09
NO330747B1 (no) 2011-07-04
HK1050191A1 (en) 2003-06-13
CA2395593C (en) 2011-08-02
AU777717B2 (en) 2004-10-28
CZ20022207A3 (cs) 2002-11-13
MA26857A1 (fr) 2004-12-20
CN1615873A (zh) 2005-05-18
US7227020B2 (en) 2007-06-05
NO20066017L (no) 2002-06-21
NO20023032L (no) 2002-06-21
AP1587A (en) 2006-03-02
CA2699568C (en) 2013-03-12
CZ301750B6 (cs) 2010-06-09
JP2012031181A (ja) 2012-02-16
HK1050191B (en) 2011-04-29
EA200200707A1 (ru) 2003-02-27
KR100910488B1 (ko) 2009-08-04
IL150388A0 (en) 2002-12-01
IL193615A0 (en) 2009-05-04
WO2001047922A2 (en) 2001-07-05
AU2209401A (en) 2001-07-09
HUP0203895A2 (hu) 2003-02-28
DZ3377A1 (fr) 2001-07-05
CA2395593A1 (en) 2001-07-05
BG66066B1 (bg) 2011-01-31
CY1110951T1 (el) 2015-06-11
WO2001047922A3 (en) 2002-01-17
JP5436507B2 (ja) 2014-03-05
US6770643B2 (en) 2004-08-03
BR0017038A (pt) 2003-01-07
HRP20020547B1 (hr) 2011-06-30
EE200200343A (et) 2003-06-16
SK288019B6 (sk) 2012-11-05
AP2006003492A0 (en) 2006-02-28
KR100755622B1 (ko) 2007-09-04
EP1990343A3 (en) 2008-12-10
KR20070050103A (ko) 2007-05-14

Similar Documents

Publication Publication Date Title
AP1917A (en) Azaindoles
DE60018571D1 (en) Hernienprothese
DE60033307D1 (en) Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE50008011D1 (en) Thixotropierungsmittel
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
PL354600A1 (en) Naphthyridine derivatives
DE60027722D1 (en) Aspartyl-protease inhibitoren
DE50002614D1 (en) Sigma-delta-modulator
DE60007505D1 (en) Propargyletherderivate
DE60028360D1 (en) Ptk-chipthermistor
DE50000137D1 (en) Spirofluorenopyrane
DE60011809D1 (en) Oxcarbazepinsuspension
DE59909975D1 (en) Testleck
DE60001313D1 (en) Imidazodiazepinderivate
DE10081629D2 (en) Seilzugbefestigung
HUP0200274A2 (en) Fitting
AU140373S (en) Bumbag
DE50009469D1 (en) Common-rail-injektor
DE60012950D1 (en) Polyacetalharzzusammensetzung
GB9912283D0 (en) Bio-power
DE50010757D1 (en) Stilbenaufheller
DE50012999D1 (en) Stirnwandisolation